Late-breaking Trial Presentations at ESC 2017

September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinical Trial presentations highlighting the latest cardiovascular science. ESC 2017 includes 21 late-reaking clinical trials, presented and discussed in four Hot Line sessions, plus late breaking results from 12 registries and 12 clinical trial updates. Some of the key presentations with links to the article were:

• SPYRAL HTN-OFF MED Study: Results Show Efficacy, Safety of Renal Denervation

• CASTLE-AF Study: Results Indicate Catheter Ablation of Atrial Fibrillation as First-Line Treatment for Heart Failure Patients

• CANTOS Trial: Designed to directly test the inflammatory hypothesis of atherothrombosis by randomly allocating post-myocardial infarction patients to one of three doses of canakinumab (a monoclonal antibody targeting interleukin 1-beta) or to placebo. 

• DETO2X-AMI: This registry-based randomized clinical trial done in 35 hospitals across Sweden examines if giving oxygen to patients with myocardial infarction is useful or if it actually does harm.

• COMPASS Trial: This study looks whether rivaroxaban, either alone or with aspirin, is superior to aspirin alone for the prevention of myocardial infarction, stroke and cardiovascular death in patients with stable coronary or peripheral artery disease.
 
• EMANATE Trial: This study looks at apixaban versus conventional therapy in anticoagulation-naive patients with atrial fibrillation undergoing cardioversion.
 
• LAACS Study: This randomized study examined whether surgical closure of the left atrial appendage (LAA) during open heart surgery protects the brain against thromboembolic damage.
 
• VIVA Trial: Results of this study will reveal the mortality impact and cost-effectiveness of combined screening for abdominal aortic aneurysm (AAA), peripheral artery disease (PAD) and hypertension.
 
• Phase II ORION 1 Trial: Looks at the impact of single or multiple injections of the first-in-class PCSK9 inhibitor inclirisan on low-density lipoprotein cholesterol . The study looked at establishing the dose and dosing frequency that will be required in phase III trials.
 
• FOURIER Trial: This clinical trial update will show the efficacy and safety of evolocumab added to high-intensity or moderate-intensity statin therapy in patients with clinically evident atherosclerotic cardiovascular disease.

• PURE Trial: Results will reveal the dose-response effect of fruit, vegetable and legume intake on cardiovascular disease  and mortality among 135,335 people aged 35 to 70 without prior cardiovascular disease from 18 countries on five continents.

• CLARIFY Trial: Findings from the prospective international longitudinal registry of 32,703 outpatients with stable coronary artery disease will explain how low diastolic blood pressure and increased pulse pressure contribute to the J curve in hypertensive patients with coronary artery disease.

Other Key ESC 2017 Presentations

• MobiusHD Device Shows Promise in Treatment of Resistant Hypertension

• Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial

• Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin

• Titan Nitride Oxide Coated Stent is Noninferior to Synergy Stent

For more information: www.escardio.org

Late-breaking Trials From TCT, ACC, SCAI and HRS: 

SCAI 2017 Late-Breaking Clinical Trial Presentations

Heart Rhythm Society 2017 Late-Breaking Electrophysiology Trials

ACC 2017 Late-Breaking Trials

TCT 2016 Late-breaking Trials and First Reports